Novanta 3Q 2026: Revenue $305.01M, EPS $0.05 — 10-Q Summary
Novanta reported 3Q 2026 revenue of $305.01M, up 23.1% YoY, but net income fell 81.1% to $2.02M due to higher costs. Automation segment revenue rose 16%, while Medical Solutions grew 30.3%, including $32.9M from Riverpoint Medical acquisition. Gross margins varied across segments.
How this was made

The 30-second read
Why it matters
The earnings miss may trigger short‑term sell pressure, but the revenue beat and acquisition synergies could be viewed positively over a longer horizon.
Market read
Primary earnings disclosure for a small‑cap medical‑technology firm; fresh numbers may move the stock in after‑hours trading.
What to watch
Restructuring charges are expected to taper off by 1Q 2027, which may improve margins in future quarters.
Background
Novanta Inc. filed its Q3 2026 Form 10‑Q, reporting revenue growth driven by the recent Riverpoint Medical acquisition and higher segment demand.
Ticker impact
Q3 2026 revenue rose 23.1% YoY to $305.01M, but diluted EPS fell to $0.05, an 83.3% decline from the prior quarter.
likely downside pressure as the market prices in the sharp EPS decline and higher acquisition-related costs.
Revenue beat is offset by a steep earnings drop and higher SG&A, R&D, and amortization charges, which typically weigh on the stock.
Market effects
Medical solutions segment shows strong growth from the Riverpoint Medical acquisition, potentially benefiting peers in minimally invasive surgical consumables.
No immediate regional impact beyond the company's operating markets.
Limited to investors tracking small-cap medical device and automation technology stocks.
Counterpoint
Despite the EPS miss, the 23% revenue growth and successful integration of Riverpoint could support a longer‑term upside if costs normalize.
Key entities
- CompanyNovanta Inc.
US‑listed medical device and automation technology company (ticker NOVT).
- CompanyRiverpoint Medical
Acquired minimally invasive surgical consumables business contributing $32.9M of Q3 revenue.


